

Kai Xiong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6305162/publications.pdf>

Version: 2024-02-01

17
papers

664
citations

759233

12
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

538
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Photosensitizers against Cisplatin-Resistant Cells. <i>Photochemistry and Photobiology</i> , 2022, 98, 85-91.	2.5	9
2	Photodecaging of a Mitochondria-Localized Iridium(III) Endoperoxide Complex for Two-Photon Photoactivated Therapy under Hypoxia. <i>Journal of the American Chemical Society</i> , 2022, 144, 4091-4101.	13.7	93
3	Highly cytotoxic copper(II) terpyridine complexes as anticancer drug candidates. <i>Inorganica Chimica Acta</i> , 2021, 516, 120137.	2.4	27
4	An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Angewandte Chemie</i> , 2021, 133, 4707-4715.	2.0	28
5	An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 4657-4665.	13.8	144
6	Cancer cell membrane camouflaged iridium complexes functionalized black-titanium nanoparticles for hierarchical-targeted synergistic NIR-II photothermal and sonodynamic therapy. <i>Biomaterials</i> , 2021, 275, 120979.	11.4	82
7	Autophagy-Dependent Apoptosis Induced by Apoferritin-Cu(II) Nanoparticles in Multidrug-Resistant Colon Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 38959-38968.	8.0	17
8	Iridium(III) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells. <i>Chemical Communications</i> , 2021, 57, 8308-8311.	4.1	12
9	Ferriridium: A Lysosome-Targeting Iron(III)-Activated Iridium(III) Prodrug for Chemotherapy in Gastric Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 3315-3321.	13.8	54
10	Ferriridium: A Lysosome-Targeting Iron(III)-Activated Iridium(III) Prodrug for Chemotherapy in Gastric Cancer Cells. <i>Angewandte Chemie</i> , 2020, 132, 3341-3347.	2.0	12
11	Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II. <i>Angewandte Chemie</i> , 2020, 132, 16774.	2.0	4
12	Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 16631-16637.	13.8	47
13	Boosting two-photon photodynamic therapy with mitochondria-targeting ruthenium-glucose conjugates. <i>Chemical Communications</i> , 2020, 56, 5839-5842.	4.1	27
14	A biotinylated ruthenium(II) photosensitizer for tumor-targeted two-photon photodynamic therapy. <i>Chemical Communications</i> , 2019, 55, 10972-10975.	4.1	42
15	Mitochondria-targeting cyclometalated iridium(III) complexes for tumor hypoxic imaging and therapy. <i>Inorganic Chemistry Frontiers</i> , 2019, 6, 1003-1010.	6.0	35
16	Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer agents. <i>Biochimie</i> , 2016, 125, 186-194.	2.6	31
17	Chiral Rull-PtII Complexes Inducing Telomere Dysfunction against Cisplatin-Resistant Cancer Cells. <i>Angewandte Chemie</i> , 0, , .	2.0	0